Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.52 |
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.50 |
| ▸ | CYP2E1 | P05181 | 3/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.47 |
| ▸ | AR | P10275 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6871817 | 0.90 | NPC1 (0.64) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6872792 | 0.88 | NPC1 (0.54) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6884539 | 0.81 | NOS2 (0.67) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL10921305 | 0.81 | RAB9A (0.55) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL8500232 | 0.80 | NOS3 (0.56) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6884037 | 0.80 | ATP4A (0.38) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL10920878 | 0.80 | SMN1; SMN2 (0.58) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6873254 | 0.80 | RAB9A (0.81) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL9526788 | 0.76 | ATP4A (0.57) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL10924416 | 0.75 | CYP2D6 (0.43) | RAB9ANPC1CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4628098-A | Including Prevacid (TM) lansoprazole, 2-(3-methyl-4-(2,2,2-trifluoroethoxy)-5-methyl-pyrid-2 -yl)methylsulfinylbenzimidazole; proton pump inhibitors, antiulcer, antisecretory agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-12-09 | — | — | US | claimed |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | ATOPIX THERAPEUTICS LTD (GB) | 2014-11-06 | — | — | US | disclosed |
| EP-2790696-A1 | COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | Atopix Therapeutics Limited (GB) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013088109-A1 | COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | OXAGEN LIMITED (GB) | 2013-06-20 | — | — | WO | disclosed |
| EP-1572098-A2 | METHOD OF TREATING SNORING AND OTHER OBSTRUCTIVE BREATHING DISORDERS | Sohn, Stearns & Stern (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040258621-A1 | Method of treating snoring and other obstructive breathing disorders | SOHNSTEARNS & STERN | 2004-12-23 | — | — | US | disclosed |
| WO-2004034973-A2 | METHOD OF TREATING SNORING AND OTHER OBSTRUCTIVE BREATHING DISORDERS | STERN WARREN (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040258621-A1 | Method of treating snoring and other obstructive breathing disorders | HRH2, HRH1, HRH4 | RAB9A 2407/4885NPC1 646/4885CYP1A2 230/4885 |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | HRH2, HRH1, HRH4 | RAB9A 561/4885NPC1 1315/4885CYP1A2 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.